Eureka Thera’s CAR-T treatment shrinks liver cancer in small study. What’s the big deal? Just ask Sloan-Kettering and Germany’s Boehringer.

The News: Eureka Therapeutics Inc., a closely held biotechnology company, said that liver cancer patients getting its CAR-T therapy responded to the treatment, one of the first times the immune-system… Read more »

Researchers say autobiographical memory test may foretell Alzheimer’s risk. Study invokes friends, relatives and sparks uneasy self-reflection.

The News: Testing how well people remember past events in their lives could help medical professionals make early predictions about who is at risk for developing Alzheimer’s disease (AD), according… Read more »

Flood gates for medical IPO filings still wide open as Labor Day holiday only speeds up pace for hopefuls.

The somber mood of summer’s waning days and shortened work week didn’t cool the blistering pace of biotech and other healthcare IPO news. Almost makes me feel sorry for the… Read more »

Weekly Medical Stock Spotlight: 3 big winners and 2 total duds.

1) ProQR Therapeutics NV (Nasdaq:PRQR) led advancing issues on the Labor Day-shortened week, soaring 107% over the week to $15.80 on Friday (August 31, 2018). The upward move came after the… Read more »

Novo Nordisk buys UK biotech startup for $800M, fueling blockbuster hopes for “smart” insulin. This Danish behemoth is a smart Buy.

The News: Novo Nordisk A/S (Bagsvaerd) has acquired UK start-up Ziylo Ltd. (Bristol) in a deal worth up to $800 million in a bid to develop the world’s first “smart”… Read more »

India’s huge pharma/consumer health market in crosshairs of world’s biggest drugmakers. China, Japan, Korea lurking as Asia joins fray with West.

The News: GlaxoSmithKline PLC‘s (London) Indian consumer health unit is drawing the attention of more big-name suitors as the magnitude of the potential there is coming into clearer focus. After… Read more »

Korean push into biotech space meant to challenge China, as ViroMed buys US plant for new gene-therapy development. High risk/reward bet, only for the brave.

The News: ViroMed Co. Ltd., the Korean biotech, has seen companies miss out on approvals for novel therapies because the FDA had problems with their manufacturing processes. With its first treatment… Read more »

ViiV Healthcare’s success with monthly combo HIV med making Gilead sweat over its HIV franchise. After World Cup fiasco, England chasing California in $$$$/rep race.

The News: GlaxoSmithKline PLC’s (London) ViiV Healthcare unit now has results to support a two-drug monthly injection co-developed with Johnson & Johnson (New Brunswick NJ) as it pushes ahead with its ambition… Read more »

Solution to China’s vaccine scandal now in the hands of rising blockchain maven VeChain. Buy a few tokens?

The News: A new production scandal has undermined Chinese citizens’ confidence in domestically made vaccines, and the tech community is suggesting the solution may lie in a highly touted technology: blockchain…. Read more »

Organoids have landed in Austria: New 3D-printed placenta poised to solve life-threatening questions. But a little too late after Dutch trial runs amok.

The News: Austrian researchers have created a miniature 3D model of the human placenta, which could help us understand the causes of pregnancy complications. The human placenta plays a vital… Read more »